Urinary safety biomarkers Drug-induced kidney injury Nephrotoxicity Drug-induced phospholipidosis Kidney injury molecule-1 (KIM-1) Bis(monoacylglycerol)phosphate A B S T R A C T Drug-induced kidney injury (DIKI) is a major concern in drug risk assessment given its clinical importance and the absence of a sensitive/specific method of diagnosis. Pharmaceutical regulatory agencies have qualified and issued letters of support for new biomarkers to better evaluate DIKI in nonclinical toxicity and clinical studies. Additional efforts have focused on drug-induced phospholipidosis (DIPL) and its potential link with collateral renal damage. The combined use of urinary biomarkers is an efficient way to evaluate renal safety in nonclinical and clinical studies. Eight FDA/EMA/PMDA qualified (or supported) urinary biomarkers, including kidney injury molecule-1 (KIM-1), β2-microglobulin (B2M), clusterin (CLU), cystatin C (CysC), trefoil factor 3 (TFF3), neutrophil gelatinase-associated lipocalin (NGAL), osteopontin (OPN), and alpha-glutathione S-transferase (α-GST), were quantified by multiplex UPLC-MS/MS in a repeat dose study of gentamicin in rats. Rats administered gentamicin at 100 mg/kg/day for 2 weeks developed renal lesions detected by histopathology. Biomarkers of tubular damage (CLU, KIM-1, OPN) increased 9.8, 34.7, and 35.6-fold (relative to concurrent controls), respectively, after 2 weeks of dosing. Biomarkers of glomerular damage and/or impairment of tubular reabsorption (CysC, B2M) increased 11.7 and 22.6-fold. NGAL and α-GST increased < 3-fold after 2 weeks of dosing. TFF3 was comparable to concurrent controls. The elevated biomarker concentrations met PSTC threshold criteria and were consistent with mechanisms of gentamicin nephrotoxicity. Increased urinary di-22:6-BMP indicated concomitant DIPL as confirmed by TEM. This work provides evidence supporting the combined use of the DIKI biomarker panel and di-22:6-BMP as a biomarker of DIPL in drug risk assessment.
Introduction
Monitoring nephrotoxicity with traditional parameters, such as serum creatinine (sCr) and blood urea nitrogen (BUN), lacks adequate sensitivity for the early detection of clinically relevant kidney injury (EMA, 2016; FDA, 2016) . Translatable biomarkers with greater sensitivity and specificity than sCr and BUN are needed to better evaluate drug-induced kidney injury (DIKI) in nonclinical drug development and clinical trials. To address this need, the United States Food and Drug Administration (FDA), European Medicines Agency (EMA), and Japanese Pharmaceuticals and Medical Devices Agency (PMDA) have squalified and/or issued letters in support of several new urinary proteins for the diagnosis of specific kidney pathologies (Table 1) .
Drug-induced phospholipidosis (DIPL) is a contributing factor to the renal tubular toxicity of cationic amphiphilic drugs (CADs) and aminoglycoside antibiotics at clinically relevant dose levels (Quiros et al., 2011) . Ongoing studies addressing DIPL, an earlier and easier diagnosis, and its potential link to collateral tissue damage, reflect the importance of DIPL to industry and regulators (Willard and De Felice, 2016) . The lysosomal phospholipid di-22:6-bis(monoacylglycerol) phosphate (BMP) is a sensitive and specific biomarker of tissue DIPL that can be monitored in the plasma/serum and urine . Di-22:6-BMP provides a biologically relevant, direct link for monitoring DIPL in target tissues/organs and has the potential to greatly impact the strategy of testing for DIPL (Tarrant, 2017) .
The combined use of the new urinary protein panel for kidney injury and di-22:6-BMP for DIPL offers a promising approach to evaluate the renal safety of drug candidates and marketed drugs. These urinary safety biomarkers should enable earlier and more specific detection of kidney injury, especially when used in combination, than traditional means of monitoring nephrotoxicity and provide information related to the location of damage (Fuchs and Hewitt, 2011; Waring and Moonie, 2011; Zhou et al., 2008) . The FDA/EMA/PDMA qualified DIKI biomarkers are urinary kidney injury molecule-1 (KIM-1), β2-microglobulin (B2M), clusterin (CLU), cystatin C (CysC), trefoil factor 3 (TFF3), albumin, total protein, and renal papillary antigen-1 (RPA-1) (BQRT, 2009; FDA, 2010a,b) . Other urinary proteins that are actively being investigated as DIKI biomarkers are urinary neutrophil gelatinase-associated lipocalin (NGAL), osteopontin (OPN), and alpha-glutathione S-transferase (α-GST) (Critical Path Institute, 2014; FDA, 2014; Phillips et al., 2016) . These biomarkers have been evaluated in multiple data sets from rat toxicological studies submitted to the regulatory agencies by the Nephrotoxicity Working Group of the Critical Path Institute Predictive Safety Testing Consortium (PSTC) (EMA, 2014; FDA, 2008 FDA, , 2009 ) and the International Life Sciences Institute Committee on Biomarkers of Nephrotoxicity of the Health and Environmental Sciences Institute (ILSI HESI) (EMA, 2010a , b, FDA, 2010a ,b, Takei, 2015 .
Di-22:6-BMP has been evaluated in multiple data sets from rat toxicological studies conducted within the pharmaceutical industry and by the FDA (Baronas et al., 2007; Tengstrand et al., 2010; Thompson et al., 2012a,b; Mesens et al., 2012; Willard, 2010; Philips et al., 2009; Liu et al., 2014; Hsieh and Tengstrand, 2015) . Compounds that induce phospholipidosis are typically associated with higher incidences of pathological findings than non-phospholipidosis inducing compounds (Barone et al., 2012) . Di-22:6-BMP is significantly more predictive of DIPL than other species of phospholipids, and is the least predictive of tissue injury (Thompson et al., 2012a) .
Various single-and multiplex immunoassays are commercially available for the detection and quantitation of urinary safety biomarkers (Fuchs and Hewitt, 2011 ). An immunoassay for the specific detection of urinary di-22:6-BMP has yet to be made available. Although traditional enzyme-linked immunosorbent assays (ELISAs) are important research tools, they generally report only on a single analyte at a time per aliquot of sample. An approach using ELISAs sequentially or in parallel to measure multiple biomarkers per sample can be timeconsuming, sample-depleting, and costly. These limitations become especially relevant in the context of clinical trials, where the volume of specimen collected is typically limited and accurate/reproducible concentration data are desired for multiple biomarkers at a time. Additional issues related to immunoassays are the availability of high quality (i.e. stable and specific) antibodies to minimize cross-reactivity, non-specific binding and interfering endogenous substances (FDA, 2009) .
Immuno-based multiplex techniques have been developed to detect urinary biomarkers and are promoted as requiring less sample and more cost effective than traditional ELISAs (Fuchs and Hewitt, 2011; Zhang et al., 2013) . However, in addition to the issues above, these formats may poses technical challenges, including the optimization of multianalyte sensitivities and working ranges (Beaver and Roby-Peters, 2011; FDA, 2009; Gan and Patel, 2013; Hidi, 2010; Kingsmore, 2006) . Moreover, managing different lots of immunoassay kits (lot to lot antibody changes) can impact the performance of the immunoassay and increase the variability of reported biomarker levels.
A recent FDA review of the analytical studies submitted for the qualification of clinical safety biomarkers reported significant interferences (from 21.9 to 218.8%) on the measurement of urinary KIM-1, CLU, CysC, NAG, NGAL, and OPN by ELISA and colorimetric techniques (FDA, 2018a,b) . The test results in samples with low/normal concentrations of urinary safety biomarkers may be inaccurate because of high albumin, hemoglobin, and blood contamination. Data also showed that some of the biomarkers were impacted by whether they were stabilized (e.g. use of protease inhibitors) or not. In addition, although many immunoassays and kits are described by the manufacturers as having high sensitivity and excellent specificity for the detection of a certain biomarker (e.g. KIM-1, CLU, etc.), these studies are limited by the availability of related isoforms, current skills and knowledge. For example, it may not be possible for manufactures to complete the crossreactivity detection between KIM-1 and all its analogues, therefore, cross reaction may still exist (Wuhan Fine Biological Technology, 2018) .
The qualification of the new protein biomarkers by the FDA/EMA/ PDMA prompted us to develop a multiplexed ultra high performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method to simultaneously quantitate eight of the DIKI safety biomarkers in urine. UPLC-MS/MS is a highly specific approach for the absolute quantitation of proteins in complex biological matrices. This type of assay provides absolute quantification data over several orders of magnitude for many proteins at a time. Analyses are performed in a single acquisition using the same sample (as opposed to serial acquisitions using multiple aliquots). In contrast to antibody-based quantitation, where antibody availability and specificity are often limiting, UPLC-MS/MS assays can be configured for essentially any protein (Zhang et al., 2011) . The implementation of UPLC-MS/MS in drug development offers an efficient way to maximize the amount of biomarker data from a limited number or volume of biological samples (Hidi, 2010) .
The key objective was to quantitate the urinary safety biomarkers KIM-1, B2M, CLU, CysC, TFF3, NGAL, OPN and α-GST in a repeat dose study of gentamicin in rats. Gentamicin is an aminoglycoside antibiotic and known nephrotoxicant which induces DIPL in laboratory animals and humans at therapeutic doses (Quiros et al., 2011; Selby et al., 2009 ). Urinary di-22:6-BMP was used as a biomarker of DIPL. Renal pathology was examined by histopathology and transmission electron microscopy (TEM). The changes in urinary safety biomarkers of DIKI/ DIPL were evaluated in the context of gentamicin-associated renal toxicity in rats.
Materials and methods

Animals
The animal study was conducted at Sinclair Research Center, LLC (Auxvasse, MO) in accordance with the USDA Animal Welfare Act and Public Health Service Policy for the Humane Care and Use of E. Tengstrand et al. Toxicology and Applied Pharmacology 366 (2019) 54-63 Laboratory Animals and compliant with Institutional Animal Care and Use Committee (SRC IACUC Protocol S14940). Male Sprague Dawley rats 9 weeks of age (at start of study) were obtained from Charles River Laboratories (Raleigh, NC). The animals were housed individually and given ad libitum access to water and pelleted rodent chow. Following an acclimation period of at least five days, the rats were weighed (target 200 to 250 g at start of study) and randomly assigned to study groups by body weight.
Test article
Gentamicin sulfate was purchased from Enzo Life Sciences (Farmingdale, NY) and prepared daily as a 100 mg/mL (expressed as free base) solution in 0.5% w/v hydroxypropyl methylcellulose (HPMC)/0.2% Tween 80 in distilled water.
Study design and procedures
Male Sprague-Dawley rats received gentamicin formulated in vehicle at 100 mg/kg or vehicle only once daily (QD) for 14 consecutive days. The study design and procedures are summarized in Table 2 . Both gentamicin formulation and the vehicle (0.5% w/v HPMC/0.2% Tween 80) were administered via subcutaneous (SC) injection at a daily volume of 10 mL per 100 g body weight. Animals were not fasted for study procedures. During the dosing period, animals were observed for mortality and moribundity at least twice daily. Clinical observations were performed daily (~1 hour post dose). On Day 15, animals from both groups were humanely euthanized via carbon dioxide (CO 2 ) gas.
Urine collections
Animals were transferred to rodent metabolism cages for urine collection at room temperature. Urine was continuously collected for 24 h prior to dosing on Day 1 (predose) and for 24 hours post last dose (Day 15). Special care was taken to ensure the urine did not overflow the containers during the 24-hour period. The total volume of urine was measured and recorded (to the nearest mL). All produced urine was transferred into an appropriately-sized labeled polypropylene container and stored at −70°C until biomarker analysis.
Tissue collection
Kidneys were examined at necropsy for macroscopic abnormalities, weighed, and divided approximately in thirds. One third of the tissue was flash frozen in a 2 mL labeled screw cap vial with liquid nitrogen. Flash frozen samples were stored at −70°C. Another third of the tissue was placed in 10% buffered formalin (approximately 1:10 tissue/fixative) and maintained at room temperature. The last third of the tissue was placed in 1 mL of fixative (2.5% PFA /2.5% Glutaraldehyde in 0.1 M Sodium Cacodylate buffer pH 7.4). The tissues were cut into small pieces in the fixative for better preservation (~2 mm cubes) and stored at 4°C.
Histopathological examination
Histopathological evaluation of tissue sections was performed by the Rodent Pathology Core at Harvard Medical School (Boston, MA). The tissues were fixed in 10% buffered formalin. The tissues were dehydrated through increasing concentrations of alcohol, saturated with xylene, and then embedded in paraffin. Paraffin-embedded micron sections were cut and stained with hematoxylin and eosin (H&E).
Transmission electron microscopy and analysis
Sample preparation and imaging using TEM was performed at the Harvard Medical School Electron Microscopy Facility (Boston, MA). Small pieces (1-2 mm cubes) of renal tissue were cut and fixed in 2.5% PFA/2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer pH 7.4, washed with 0.1 M cacodylate buffer, and post-fixed in 1% osmiumtetroxide/1.5% potassium ferrocyanide followed by washes in water and incubation in 1% uranyl acetate for 1 h. The tissues were washed and dehydrated in alcohol. The samples were embedded in TAAB Epon resin (Marivac Canada Inc., St. Laurent, Canada). Ultrathin sections (about 60 nm) were cut on a Reichert Ultracut-S microtome (Leica Microsystems, Wetzlar, Germany), picked up on to copper grids stained with lead citrate and examined in a JEOL 1200EX Transmission Electron Microscope (TEM) (JEOL, Peabody, MA). Images were recorded with an AMT 2k CCD camera (Advanced Microscopy Techniques, Corp., Woburn, MA). The images were evaluated for the presence of membranous bodies that are characteristic of DIPL.
Kidney injury biomarker assay 2.8.1. Digestion with trypsin
Concentrations of eight urinary proteins (KIM-1, B2M, CLU, CysC, TFF3, NGAL, OPN, and α-GST) were simultaneously determined based on representative signature peptides derived from an optimized trypsin digestion procedure. Rat urine was denatured, alkylated with iodoacetamide and digested with trypsin. The enzymatic reaction was quenched with 10% formic acid in water.
Further processing
After digestion, the samples were centrifuged at 10,000 rpm for 10 min. The supernatant was transferred to a new sample plate and mixed with 0.1% formic acid in 90/10 water/acetonitrile (v/v). Internal standard spiking solution was added. The samples were mixed well by pipetting. The sample plate was covered with heating foil and submitted for UPLC-MS/MS.
Quantitative UPLC-MS/MS conditions
Signature peptide levels were quantified in rat urine using a SCIEX Triple Quad™ 6500 LC-MS/MS System and UPLC chromatography. Corresponding mass-shifted, stable isotope-labeled peptides were employed as internal standards. Injections were made using a Shimadzu Nexera XR ultra high-performance liquid chromatograph (UPLC) system (Shimadzu Scientific Instruments, Japan). Mobile phase A was 0.1% formic acid in water. Mobile phase B was 0.1% formic acid in 90:10 acetonitrile/water (v/v). The total running time per sample was E. Tengstrand et al. Toxicology and Applied Pharmacology 366 (2019) 54-63 20 min. A SCIEX Triple Quad™ 6500 mass spectrometer equipped with an IonDrive™ Turbo V source was used in positive electrospray ionization (ESI) mode (SCIEX, Framingham, MA). The instruments were controlled by Analyst® 1.6 software. Two MRM transitions were used to monitor each signature peptide, and one MRM transition was used to monitor each internal standard.
Calibration and data processing
The intensities of the KIM-1, B2M, CLU, CysC, TFF3, NGAL, OPN, and α-GSTsignature peptides and internal standards were determined by integration of extracted ion peak areas using MultiQuant™ 3.0 software (SCIEX, Framingham, MA). The signature peptide (quantifier) to internal standard peak area ratio was used for comparison across the samples. Calibration curves were prepared by plotting the signature peptide to internal standard peak area ratio vs. concentration (ng/mL). Data points were selected from calibration samples at the beginning and end of the analytical run. The model for the calibration curves was linear with (1/x 2 ) weighting consistent throughout the study. Microsoft Excel 2010 (Microsoft, Redmond, WA) was used for all other calculations. The measured concentrations of the signature peptides were converted to protein concentrations.
Phospholipidosis biomarker analysis
The drug-induced phospholipidosis (DIPL) biomarker di-22:6-BMP was extracted from rat urine using the liquid-liquid phase extraction technique described by Liu et al., 2014 . Urinary di-22:6-BMP concentrations were quantitated using a SCIEX Triple Quad™ 6500 LC-MS/ MS System. Di-myristoyl (14:0)-bis(monoacylglycerol) phosphate (di-14:0-BMP) was used as an internal standard. Full details related to the sample preparation and analysis are found in Liu et al., 2014.
Urinary creatinine
Concentrations of urinary creatinine were measured by colorimetric assay (method of Jaffé) with Parameter™ Creatinine Assay test reagents (R&D Systems, Minneapolis, MN) using a BioTek™ ELx800™ absorbance microplate reader with Gen5 ™ Microplate Reader and Imager Software 2.09 (Fisher Scientific, Hampton, NH).
Presentation of urinary biomarker data
In order to adjust for changes in urine flow, biomarker values were normalized for urinary creatinine content by dividing the measured concentration of the biomarker by the urinary concentration of creatinine. This is the method that has seen the most widespread use and which was applied in all rat studies in which data used to support qualification by the regulatory agencies was generated (Gautier et al., 2014) . Additionally, Hass et al. (1997) indicated that normalization by creatinine excretion allows for detection of changes in urinary parameters in rats if the change exceeds a 40% deviation of the normal value.
Statistical analysis
Biomarker values (normalized for urinary creatinine) are expressed in the text as mean ± standard deviation (SD) and presented in figures as box-and whisker plots which show the median, 25th and 75th percentiles, and the smallest and largest values in the range of data. Normalized values for each group were compared by paired t-test and were considered significant at p-value ≤ .05. Fold-differences (treated versus controls) in the concentrations of urinary biomarkers were determined after 2 weeks of gentamicin dosing relative to concurrent controls. All analyses were conducted using Microsoft Excel 2010.
Results
In-life observations
Gentamicin was relatively well-tolerated in the male SpragueDawley rats at an SC dose of 100 mg/kg/day for 2 weeks. There were no deaths and no clinical signs of toxicity recorded during the dosing period. No difference in body weight gain was observed in treated versus control rats.
Macroscopic observations in kidney
Macroscopic findings in kidneys consisted of bilateral diffuse enlargement and pale discoloration in the rats administered gentamicin. These findings correlated with tubular epithelial cell degeneration/ necrosis and tubular epithelial cell regeneration/basophilia in the cortex and medulla (described below). There were no macroscopic abnormalities observed in renal tissue of the vehicle/controls.
Kidney injury biomarkers
Urinary biomarker concentrations (normalized to urinary creatinine) are shown in Fig. 1 . The predose concentrations of all biomarkers were similar to previously reported background ranges in SpragueDawley rats. Values obtained predose were not significantly changed in the vehicle/controls after 2 weeks. In response to gentamicin-induced injury, all biomarker levels in urine were increased with the exception of TFF3. Fig. 3 shows the fold-difference in biomarkers after 2 weeks of gentamicin treatment, expressed as mean relative fold-difference between treated and controls.
Kidney injury molecule-1
The mean urinary concentration of KIM-1 was 34.7-fold higher (p ≤ .05) in rats administered daily SC doses of gentamicin at 100 mg/ kg for 2 weeks compared to the concurrent controls. The concentrations of KIM-1 ranged from 18.9 to 103 ng/mg creatinine (mean: 57.1 ± 35.3 ng/mg creatinine) in the gentamicin treated rats compared to 1.17 to 2.08 ng/mg creatinine (mean: 1.64 ± 0.457 ng/mg creatinine) in the concurrent vehicle treated controls.
β2-microglobulin
Rats administered gentamicin (100 mg/kg/day, SC) for 2 weeks had a 22.6-fold higher (p ≤ .05) mean concentration of B2M in urine relative to the concurrent controls. The concentrations of B2M ranged from 9,487 to 22,807 ng/mg creatinine (mean: 14,117 ± 5,616 ng/mg creatinine) compared to 490 to 735 ng/mg creatinine (mean: 624 ± 124 ng/mg creatinine) in the concurrent controls.
Cystatin C
The mean concentration of CysC in urine samples taken from rats administered gentamicin at 100 mg/kg/day for 2 weeks was 11.7-fold higher (p ≤ .05) relative to the concurrent vehicle treated controls. The concentrations of CysC ranged from 23,459 to 91,902 ng/mg creatinine (mean: 53,859 ± 23,633 ng/mg creatinine) in the gentamicin treated rats compared to 3516 to 6491 ng/mg creatinine (mean: 4,600 ± 1,644 ng/mg creatinine) in the concurrent controls.
Clusterin
The mean urinary concentration of CLU was 9.8-fold higher in rats administered daily SC doses of gentamicin at 100 mg/kg for 2 weeks compared to concurrent controls, but did not achieve statistical significance. The concentrations of CLU ranged from 121 to 819 ng/mg creatinine (mean: 390 ± 283 ng/mg creatinine) in the gentamicin treated rats compared to 31.3 to 47.8 ng/mg creatinine (mean: 39.79 ± 8.23 ng/mg creatinine) in the concurrent controls.
Neutrophil gelatinase-associated lipocalin
After gentamicin (100 mg/kg, SC) treatment for 2 weeks, the mean urinary concentration of NGAL was 2.7-fold higher in treated animals than concurrent vehicle/controls, but the increase was not statistically significant. NGAL concentrations ranged from 345 to 1267 ng/mg creatinine (mean: 585 ± 340 ng/mg creatinine) in the gentamicin treated rats compared to 157 to 257 ng/mg creatinine (mean: 215 ± 51.9 ng/mg creatinine) in the concurrent vehicle/controls.
Trefoil factor 3
The mean urinary TFF3 concentration in animals exposed to gentamicin (100 mg/kg/day, SC) for 2 weeks was comparable to the concurrent controls. After 2 weeks of treatment, the concentrations of TFF3 ranged from 5,083 to 16,347 ng/mg creatinine (mean: 9,305 ± 3,918 ng/mg creatinine) in the gentamicin treated rats compared to 5,957 to 14,787 ng/mg creatinine (mean: 9,799 ± 4525 ng/ mg creatinine) in the concurrent vehicle treated controls.
Osteopontin
After gentamicin (100 mg/kg, SC) treatment for 2 weeks, the mean urinary concentration of OPN was 35.6-fold higher in treated animals than concurrent vehicle/controls, but the increase was not statistically E. Tengstrand et al. Toxicology and Applied Pharmacology 366 (2019) 54-63 significant. OPN concentrations ranged from 2,236 to 14,812 ng/mg creatinine (mean: 5,100 ± 4,841 ng/mg creatinine) in the gentamicin treated rats compared to 107 to 173 ng/mg creatinine (mean: 143 ± 33.7 ng/mg creatinine) in the concurrent vehicle/controls.
α-GST
The mean urinary concentration of α-GST was 2.3-fold higher (p ≤ .05) in rats administered daily SC doses of gentamicin at 100 mg/ kg for 2 weeks compared to the concurrent controls. The concentrations of α-GST ranged from 529 to 1231 ng/mg creatinine (mean: 810 ± 275 ng/mg creatinine) in the gentamicin treated rats compared to 207 to 402 ng/mg creatinine (mean: 357 ± 42.9 ng/mg creatinine) in the concurrent vehicle treated controls.
Di-22:6-BMP Biomarker
The mean urinary concentration of di-22:6-BMP (normalized by creatinine) was 3.4-fold higher (p ≤ .05) in rats administered gentamicin compared to concurrent controls (Fig. 2) . The concentrations of di-22:6-BMP ranged from 30.3 to 422 ng/mg creatinine (mean: 191 ± 140 ng/mg creatinine) in gentamicin treated rats compared to 50.6 to 66.0 ng/mg creatinine (mean: 56.9 ± 8.06 ng/mg creatinine) for the concurrent controls.
Urinary creatinine
Normalization of the biomarker data to urinary creatinine was selected because the mean creatinine concentration and excretion were relatively comparable between the groups (treated versus control) and it was the method that was applied in the rat studies from which all the data used to support qualification by regulatory agencies were generated (BQRT, 2009; Gautier et al. 2014 ).
Histopathology of kidney
Representative micrographs of renal lesions in rat kidney after 2 weeks of daily administration of gentamicin are presented in Fig. 4 . No abnormalities were found in the renal tissue of the control rats (Fig. 4A) . Gentamicin induced renal lesions consisted mainly of epithelial cell necrosis, degeneration, and regeneration of the proximal convoluted tubules (Fig. 4B) . Dilation of the tubules, protein casts in the tubular lumina, glomerular vacuolization and interstitial lymphocytic infiltration was also observed.
Ultrastructural examination
Examination of renal tissue by TEM revealed an overabundance of multi-lamellar membranous cytoplasmic bodies and zebra bodies, indicative of gentamicin-induced phospholipidosis (Fig. 5 ). This contrasted with the normal occasional appearance of multi-lamellar bodies observed in tissue collected from the vehicle/controls. Fig. 2 . Concentrations of urinary di-22:6-BMP, a biomarker of drug-induced phospholipidosis, in rats administered gentamicin (100 mg/kg/day, SC) or vehicle (0.5% HPMC/0.2% Tween 80) only for 2 weeks. Urinary concentrations were normalized to urinary creatinine. Asterisks indicate statistically significant difference (p < .05) relative to the concurrent controls. E. Tengstrand et al. Toxicology and Applied Pharmacology 366 (2019) 54-63 
Discussion
Multiplexed assays provide an efficient way to maximize the amount of biomarker data from nonclinical study and clinical trial specimens. In this study, a targeted UPLC-MS/MS method was used to simultaneously quantitate eight urinary biomarkers of kidney injury (KIM-1, B2M, CLU, CysC, TFF3, NGAL, OPN and α-GST) in a repeat dose study of gentamicin in rats. All of the protein biomarker data was acquired in a single acquisition with the same sample aliquot (as opposed to serial acquisitions using multiple aliquots) thereby saving the time/costs associated with biomarker analyses. Urinary di-22:6-BMP, a biomarker of DIPL, was measured in a separate analysis. For future studies, the method can be configured for use across species (e.g. to monitor biomarkers in human urine) and/or include various additional exploratory biomarkers of acute kidney injury.
In this approach, urinary protein biomarkers were quantified by measuring representative "signature" peptides derived from proteolytic digestion. The signature peptides were quantified by multiple reaction monitoring (MRM) with one or more MS/MS product ions of that peptide selected for quantitation. Mass-shifted, stable isotope-labeled peptides were spiked as internal standards (ISs), which enables more precise quantification (Carr et al., 2014) . The use of a UPLC system over a high pressure liquid chromatography (HPLC) system allows using small particle-packed columns with small diameter, which dramatically increases the resolution, sensitivity, and speed of analysis (Swartz, 2007) .
While immunoassays are hindered by variations in urine pH, specific gravity, and protein/carbohydrate content (Wood et al., 2011) , the novel UPLC-MS/MS assay employed an optimized sample workflow to remove interfering matrix elements that could alter the MS response or co-elute with the target analytes. Due to the high resolution and narrow peaks in UPLC, the analytes generally co-elute less with interferences during ionization, so matrix effects are diminished, or even eliminated. A review of the analytical studies submitted for the qualification of clinical DIKI biomarkers discusses the potential impact of lack of stability on the immunoassay test results (FDA, 2018a, b) . In contrast, UPLC-MS/MS methods for protein quantitation can overcome these challenges (for example, lack of biomarker stability, lack of stability due to pH of urine, and need to add stabilizers soon after collection). In addition, UPLC-MS/MS readily addresses biomarker specificity issues associated with immunoassays by precisely measuring isoform-specific fragmentation patterns.
In this study, the mean urinary concentrations of biomarkers of acute tubular damage were higher in Sprague-Dawley rats administered gentamicin (100 mg/kg/day, SC) for 2 weeks relative to concurrent controls. The mean concentration of urinary KIM-1 was 34.7-fold higher (p ≤ .05) in the rats treated with gentamicin versus the controls. The mean concentrations of urinary CLU and OPN were 9.81 and 35.6-fold higher, respectively, although there was no statistical significance across groups. A larger sample size would have provided the benefit of increasing the statistical power of the study. Less severe (< 3-fold) differences with no statistical significance were observed in in urinary NGAL and α-GST, also markers of proximal renal tubule degeneration/ necrosis in rats. Urinary TFF3 was relatively comparable in the urine of the treated versus vehicle/controls. Urinary biomarkers of glomerular damage and/or impairment of tubular reabsorption (B2M and CysC) were 22.6-and 11.7-fold higher (p ≤ .05), respectively. The data trend was similar to those observed with gentamicin in rats in previous biomarker studies (Gautier et al., 2014; Harpur et al., 2011) . The elevated biomarker concentrations in this study were well above the threshold criteria set by the PSTC for tubular and glomerular injury in rats and consistent with the reported mechanisms of gentamicin nephrotoxicity and the development of renal lesions confirmed by histopathology (described below).
Gentamicin is an aminoglycoside antibiotic that is widely used against infections by Gram-negative microorganisms (Quiros et al., 2011; Williams et al., 1981) . Nephrotoxicity is a known main side effect of aminoglycoside antibiotics, especially of gentamicin, and also one of its main therapeutic limitations. Gentamicin nephrotoxicity is triggered by excessive drug accumulation in the epithelial cells of renal proximal tubules. The drug enters the tubular cells through pinocytosis and accumulates in the lysosomes, where it induces phospholipidosis. Tubular injury is followed by declining renal function as measured clinically by a rise in blood urea nitrogen, a fall in creatinine clearance, proteinuria, emzymeuria, and phospholipiduria (De Souza et al., 2009; Quiros et al., 2011; Williams et al., 1981) .
DIPL is a contributing factor to the renal tubular effects of many cationic amphiphilic drugs (CADs) such as chloroquine, hydroxychloroquine, amiodarone, and aminoglycosides antibiotics (e.g., gentamicin, amikacin, and tobramycin). Gentamicin induced phospholipidosis is characterized by an excessive accumulation of multi-lamellar (myeloid) or zebra bodies in renal cortex. These morphologic alterations, mimicking the inherited lysosomal storage disorder Fabry disease, have been reported with gentamicin in rats and human patients (Kacew, 1984; Sakuraba et al., 2015; Shayman and Abe, 2013) . Reported electron microscopic observations generally include evidence of intracellular swelling with respect to mitochondria and endoplasmic reticulum, and the presence of phospholipidosis. DIPL associated renal tubular effects may range from a mere loss of the brush border in epithelial cells to an overt tubular necrosis. Tubular cytotoxicity is the consequence of many interconnected actions, triggered by drug accumulation in renal epithelial cells (Quiros et al., 2011) .
BMP is a unique lysosomal phospholipid that is increased in the tissues of animals and humans with DIPL and lysosomal storage disorders (Besley and Elleder, 1986; Harder et al., 1984; Kasama et al., 1974; Rouser et al., 1968; Yamamoto et al., 1971a Yamamoto et al., , 1971b . Di-22:6-BMP, a specific species of BMP, provides a biologically relevant, direct link for monitoring drug-induced phospholipidosis (DIPL) in target tissues/organs and has the potential to greatly impact the strategy of clinical testing for DIPL (Tarrant, 2017; Willard and De Felice, 2016) . It is a biomarker of DIPL for nonclinical and clinical safety assessment of drug candidates and marketed drugs that serves as an indicator of histological DIPL which otherwise must be confirmed by TEM of tissue samples (Thompson et al., 2012a , 2012b . Clinical monitoring with BMP is recommended, especially when there is important tissue damage in nonclinical toxicology studies with DIPL and elevated BMP levels (Willard and De Felice, 2016) .
Rats treated with gentamicin (100 mg/kg/day, SC) for 2 weeks exhibited a significant increase in the drug-induced phospholipidosis (DIPL) biomarker di-22:6-BMP, concomitant with renal phospholipidosis demonstrated by transmission electron microscopy (TEM). Daily SC injections with gentamicin produced a 3.4-fold (p-value ≤.05) increase in urinary di-22:6-BMP, compared to concurrent control levels. Since BMP contributes to the multi-vesicular/multi-lamellar morphology and function of the inner lysosomal network (Schmitz and Muller, 1991) , its increase may be an early indicator of DIPL with histopathologic changes becoming more pronounced as the duration and/or severity of the DIPL increases. These findings are consistent with previous studies of gentamicin in rats in which elevated urinary di-22:6-BMP was observed and DIPL confirmed either histologically or by TEM examination (Baronas et al., 2007) .
DIPL is recognized by both the pharmaceutical industry and regulatory agencies as a significant challenge in drug development and should be evaluated on a case-by-case basis (Berridge et al., 2007; Chatman et al., 2009; FDA, 2009; Willard, 2008; Willard, 2010; Willard and De Felice, 2016) . When toxicity occurs in a PL-related target organ, such as the kidney, standard clinical pathology parameters, organspecific function tests, and novel biomarkers may be used to monitor concurrent toxicity and reversibility of toxicity (Chatman et al., 2009 ). Measurement of urinary biomarkers involves minimally invasive testing in animals and humans. This advantage over histopathological examination of cells/tissues allows the response to be monitored in real time. When DIPL is associated with tissue injury, as in gentamicin-associated kidney injury, the di-22:6-BMP biomarker response can be correlated with the toxicity time of onset and rate of progression (from urinary DIKI biomarkers), dose response curve, and exposure effect level (C max and AUC). In this way, the interpretation of the combined biomarkers would be beneficial in nonclinical and clinical settings of investigative drugs.
Diagnosis of DIKI/DIPL in humans has often been difficult due to practical and ethical concerns that limit the tissues available for study and the lack of sensitive and specific biomarkers. The newly qualified FDA/EMA/PDMA biomarkers and di-22:6-BMP offer biologically relevant, direct links for monitoring kidney injury and DIPL in nonclinical drug development and clinical trials. The FDA/EMA/PDMA recommends the voluntary use of these new biomarkers in nonclinical research alongside traditional clinical chemistry markers and histopathology to identify drug-induced acute kidney injury in the rat (Critical Path Institute, 2010; EMA, 2010a; FDA, 2010a FDA, , 2010b PMDA, 2010) .
As these novel exploratory biomarkers have yet to be broadly applied across drug development, for a given drug candidate it is important that the biomarkers be evaluated in nonclinical safety studies before they are incorporated in a clinical trial design (SAFE-T Consortium, 2017). The nonclinical studies will not only allow the drug development sponsor to link the response of the biomarker to histopathological lesions (or TEM findings for phospholipidosis) in the kidney, but also the timing of the injury and the biomarker's response. This knowledge should be used to determine whether or not the biomarkers should be used in clinical trials with the candidate drug, plus guide the relative timing for the collection of urine and evaluation of biomarker level.
With respect to clinical use, a composite measure of six biomarkers (KIM-1, CLU, CysC, NAG, NGAL, and OPN), referred to as the "PFC Index", has been qualified as clinical evidence of drug-associated renal tubular injury for use in early clinical trials (EMA, 2016; FDA, 2016; FDA, 2016; FDA, 2018a, b) . It's also been recommended to increase the use of the BMP biomarker in clinical trials of drugs that induce phospholipidosis (Willard and De Felice, 2016) .
In order to minimize the occurrence of drug-induced nephrotoxicity, it is necessary either to prevent new nephrotoxic drugs from entering the market or to detect and manage nephrotoxicity efficiently when use of a drug with nephrotoxic liability is mandated by medical need (Bonventre et al., 2010) . Confirmation of the high sensitivity or negative predictive power of the DIKI/DIPL biomarkers will be particularly useful in the evaluation of compounds under development and of marketed drugs that have demonstrated either nonclinical or potential risk of inducing nephrotoxicity with/without concomitant DIPL.
Conclusions
Sprague-Dawley rats in a repeat dose study receiving gentamicin, an aminoglycoside antibiotic, were evaluated for histopathological and biochemical evidence of nephrotoxicity. Renal lesions were detected by histopathology after 2 weeks of gentamicin dosing. Urinary KIM, CLU, B2M and Cys C were elevated well above the PSCTC threshold criteria for tubular and glomerular injury in rats and were consistent with the reported mechanisms of gentamicin nephrotoxicity. Increased concentrations of urinary di 22:6-BMP indicated concomitant phospholipidosis which was confirmed by TEM examination of renal tissue. This work demonstrates the successful application of a multiplexed UPLC-MS/MS method to investigate drug safety using a FDA/EMEA/PMDA qualified toxicity biomarker panel. For future studies, the method can be configured for use across nonclinical species, in the clinical setting, and/or to include additional exploratory biomarkers or drug-induced acute kidney injury. The combinatorial use of translatable DIKI/DIPL biomarkers has the potential to greatly impact the strategy of evaluating nephrotoxicity in drug risk assessment.
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